BAY 1895344

Drug Profile

BAY 1895344

Alternative Names: BAY1895344

Latest Information Update: 14 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Class Antineoplastics; Naphthyridines; Small molecules
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 06 Jul 2017 Phase-I clinical trials in Lymphoma (Late-stage disease) in Singapore (unspecified route) (NCT03188965)
  • 06 Jul 2017 Phase-I clinical trials in Solid tumours (Late-stage disease) in Singapore (unspecified route) (NCT03188965)
  • 21 Jun 2017 Bayer plans a phase I trial for Solid tumours and Lymphoma(Late-stage disease) in USA, Singapore and United Kingdom (NCT03188965)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top